Conceptus(R) to Participate in the 25th Annual ROTH Investment Conference

Conceptus(R) to Participate in the 25th Annual ROTH Investment Conference

MOUNTAIN VIEW, Calif., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Conceptus, Inc. 
(Nasdaq:CPTS), developer of the Essure^® procedure, the leading surgery-free
permanent birth control method, announced today that Company management is
planning to present at the 25th Annual ROTH Conference on Tuesday, March 19,
2013 at 11:30 a.m. Pacific time at the Ritz-Carlton Hotel in Laguna Niguel,
California.

A live webcast of the presentation will be available on the company's website
at www.conceptus.com. When accessing the webcast through the Conceptus site,
select "Investors" then select "Events and Presentations." The archived replay
will be available following the live presentation.

About the Essure^® Procedure

The Essure procedure, FDA approved since 2002, is the only surgery-free and
hormone-free permanent birth control method that can be performed in the
comfort of a physician's office in less than 10 minutes (average hysteroscopic
time) without the risks associated with general anesthesia or tubal ligation.
Soft, flexible inserts are placed in a woman's fallopian tubes through the
cervix without incisions. Over the next three months, the body works with the
inserts to form a natural barrier in the fallopian tubes to prevent sperm from
reaching the egg. Three months after the Essure procedure, an Essure
Confirmation Test is given to confirm that the inserts are in place and that
the fallopian tubes are blocked, verifying that the patient can rely on Essure
for permanent birth control.

The Essure procedure is 99.83% effective based on five years of follow up with
zero pregnancies reported in clinical trials, making it the most effective
permanent birth control available.Essure's 10-year commercial data tracks
closely with its five-year clinical results, and Essure has been proven and
trusted by physicians since 2002.The Essure procedure is covered in the U.S.
by most public and private insurance plans and approximately 730,000 women
worldwide have undergone the procedure.

About Conceptus^®, Inc.

Conceptus, Inc. is the global leader in the development and commercialization
of innovative device-based solutions in permanent birth control. The Company
manufactures and markets the Essure Permanent Birth Control System.

The Conceptus, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7961

Please visit www.essure.com for more information on the Essure procedure.
Patients may call the Essure Information Center at 1-877-ESSURE-1 with
questions or to find a physician in their area.

© 2013 Conceptus, Inc.— All rights reserved.

CONTACT: Investor and Public Relations Contact:
         Lynn Pieper
         Westwicke Partners
         (415) 202-5678
         lynn.pieper@westwicke.com

Conceptus, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.